Darrell Paul Baker from 1534 Trolley Rd, Pville, AL 36066, age 79, Phone: (334) 300-9082

Professional Records

Lawyers & Attorneys

Darrell Baker - Lawyer

View page

Office:

Baker & Whitt, PLLC

Specialties:

General Practice
Litigation
Medical Malpractice Defense
Products Liability Defense
General Liability Defense

ISLN:

909300317

Admitted:

1981

University:

Louisiana Tech University, B.A., 1976

Law School:

University of Arkansas, J.D., 1981

Resumes

Darrell Baker Baltimore, MD

View page

Work:

Windsor Mill Middle School

Oct 2013 to 2000
Additional Assistant
Chesapeake Spice Company
Belcamp, MD
Feb 2013 to Sep 2013
Report any discrepancies or problems during formulation to Supervisor
Package DriverBaltimore, MD
Feb 2011 to May 2012
Broadway Services
Baltimore, MD
Dec 2008 to Nov 2010
Security Officer
Frankford Nursing Facility
Baltimore, MD
Nov 2007 to Dec 2007
Changes
Baltimore, MD
Sep 2005 to Nov 2006
Sales Associate
McDonald's
Baltimore, MD
Sep 2003 to Sep 2005
Crew Member

Business Records

Name / Title

Company / Classification

Phones & Addresses

Mr. Darrell L. Baker

Darrell Bakers Plumbing
Professional Services (General)

936 Mountain Creek Road, Apartment H77, Chattanooga, TN 37405

Darrell Baker

RIVERWOOD SADDLEBREDS, LTD

Darrell O. Baker

CHENAL STORAGE, INC

Darrell Baker
Principal

The Ho Made
Eating Place

21353 Hwy 371, Cotton Valley, LA 71018

Darrell Baker
Principal

Aquahelp
Business Services at Non-Commercial Site

1300 Wembrough Ct, Silver Spring, MD 20905

News

FDA approves Breo Ellipta for adults with asthma

View page

Breo Ellipta is our second asthma treatment to be approved in the United States in the past year, and now provides physicians with a range of treatment options delivered via the Ellipta inhaler to meet the needs of appropriate adult patients with differing asthma severities, Darrell Baker, senior

Date

May 01, 2015

Source:

Google

GSK and Theravance's Breo Ellipta gets FDA approval to treat asthma in adults

View page

GSK Global Respiratory Franchise senior vice-president and head Darrell Baker said: "Asthma is a variable condition and guidelines recommend a stepwise approach to treatment with the aim of achieving asthma control.

Date

May 01, 2015

Category:

Health

Source:

Google

Glaxo could soon tap the second half of a $6B respiratory market

View page

We will continue to work closely with the FDA while it considers the committees recommendations and our aim is to answer any outstanding questions to enable them to make a fully informed decision, says Darrell Baker, senior vice president and head of GSK Global Respiratory Franchise.

Date

Mar 20, 2015

Category:

Health

Source:

Google

FDA Panel Recommends Approval Of GSK Asthma Drug For Adults But Not ...

View page

related to Breo Ellipta for asthma. We will continue to work closely with the FDA while it considers the Committee's recommendations and our aim is to answer any outstanding questions to enable them to make a fully informed decision," said Darrell Baker, SVP & Head, GSK Global Respiratory Franchise.

Date

Mar 19, 2015

Category:

Health

Source:

Google

GSK receives FDA approval for Arnuity(TM) Ellipta(R) (fluticasone furoate) in the ...

View page

Darrell Baker, SVP & Head, GSK Global Respiratory Franchise, said, "The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expan

Date

Aug 20, 2014

Category:

Health

Source:

Google

GSK, Therevance Expect LAMA/LABA COPD Drug Filing with FDA by Year End

View page

safety study and two replicate 12-week crossover exercise studies.We are very encouraged by the results of these initial studies for our LAMA/LABA, an important cornerstone of our broad respiratory development portfolio, comments Darrell Baker, svp respiratory portfolio optimization leader at GSK. Su

Date

Jul 02, 2012

Category:

Health

Source:

Google

GSK, Theravance Expect COPD Drug Filing with FDA by Year End

View page

study, and two replicate 12-week crossover exercise studies. We are very encouraged by the results of these initial studies for our LAMA/LABA, an important cornerstone of our broad respiratory development portfolio, comments Darrell Baker, svp, respiratory portfolio optimization leader at GSK. Su

Date

Jul 02, 2012

Category:

Health

Source:

Google

Publications